1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Baker Bros. Advisors Lp Buys Seagen Inc, Prelude Therapeutics Inc, Kymera Therapeutics Inc, Sells Seagen Inc, Principia Biopharma Inc, Neurocrine Biosciences Inc

New York, NY, based Investment company Baker Bros. Advisors Lp (Current Portfolio) buys Seagen Inc, Prelude Therapeutics Inc, Kymera Therapeutics Inc, Global Blood Therapeutics Inc, Horizon Therapeutics PLC, sells Seagen Inc, Principia Biopharma Inc, Neurocrine Biosciences Inc, Tricida Inc, Insmed Inc during the 3-months ended 2020Q3, according to the most recent filings of the investment company, Baker Bros. Advisors Lp. As of 2020Q3, Baker Bros. Advisors Lp owns 114 stocks with a total value of $24.9 billion. These are the details of the buys and sells.

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to https://www.gurufocus.com/guru/baker+bros.+advisors+lp/current-portfolio/portfolio

These are the top 5 holdings of BAKER BROS. ADVISORS LP
  1. Seagen Inc (SGT) - 47,269,424 shares, 37.19% of the total portfolio. New Position
  2. BeiGene Ltd (BGNE) - 13,301,597 shares, 15.32% of the total portfolio. Shares added by 12.94%
  3. Incyte Corp (INCY) - 31,999,398 shares, 11.54% of the total portfolio.
  4. ACADIA Pharmaceuticals Inc (ACAD) - 41,904,586 shares, 6.95% of the total portfolio.
  5. Alexion Pharmaceuticals Inc (ALXN) - 8,760,794 shares, 4.03% of the total portfolio.
New Purchase: Seagen Inc (SGT)

Baker Bros. Advisors Lp initiated holding in Seagen Inc. The purchase prices were between $123.22 and $162.9, with an estimated average price of $141.98. The stock is now traded at around $144.20. The impact to a portfolio due to this purchase was 37.19%. The holding were 47,269,424 shares as of .

New Purchase: Prelude Therapeutics Inc (PRLD)

Baker Bros. Advisors Lp initiated holding in Prelude Therapeutics Inc. The purchase prices were between $26.2 and $30.13, with an estimated average price of $28.24. The stock is now traded at around $46.91. The impact to a portfolio due to this purchase was 1.23%. The holding were 10,118,636 shares as of .

New Purchase: Kymera Therapeutics Inc (KYMR)

Baker Bros. Advisors Lp initiated holding in Kymera Therapeutics Inc. The purchase prices were between $26.1 and $33.28, with an estimated average price of $30.49. The stock is now traded at around $45.81. The impact to a portfolio due to this purchase was 0.25%. The holding were 1,959,211 shares as of .

New Purchase: Pacific Biosciences of California Inc (PACB)

Baker Bros. Advisors Lp initiated holding in Pacific Biosciences of California Inc. The purchase prices were between $3.61 and $9.87, with an estimated average price of $5.74. The stock is now traded at around $14.41. The impact to a portfolio due to this purchase was 0.13%. The holding were 3,250,000 shares as of .

New Purchase: Athira Pharma Inc (ATHA)

Baker Bros. Advisors Lp initiated holding in Athira Pharma Inc. The purchase prices were between $16.02 and $18.46, with an estimated average price of $16.7. The stock is now traded at around $23.30. The impact to a portfolio due to this purchase was 0.07%. The holding were 882,352 shares as of .

New Purchase: Harmony Biosciences Holdings Inc (HRMY)

Baker Bros. Advisors Lp initiated holding in Harmony Biosciences Holdings Inc. The purchase prices were between $30.96 and $44.39, with an estimated average price of $36.62. The stock is now traded at around $46.65. The impact to a portfolio due to this purchase was 0.05%. The holding were 400,000 shares as of .

Added: Global Blood Therapeutics Inc (GBT)

Baker Bros. Advisors Lp added to a holding in Global Blood Therapeutics Inc by 1858.24%. The purchase prices were between $52.76 and $74.49, with an estimated average price of $63.55. The stock is now traded at around $43.57. The impact to a portfolio due to this purchase was 0.19%. The holding were 920,375 shares as of .

Added: Horizon Therapeutics PLC (HZNP)

Baker Bros. Advisors Lp added to a holding in Horizon Therapeutics PLC by 233.25%. The purchase prices were between $55.23 and $79.93, with an estimated average price of $68.64. The stock is now traded at around $69.04. The impact to a portfolio due to this purchase was 0.15%. The holding were 666,500 shares as of .

Added: CymaBay Therapeutics Inc (CBAY)

Baker Bros. Advisors Lp added to a holding in CymaBay Therapeutics Inc by 113.59%. The purchase prices were between $3.32 and $7.24, with an estimated average price of $5.33. The stock is now traded at around $7.19. The impact to a portfolio due to this purchase was 0.05%. The holding were 3,252,542 shares as of .

Added: Replimune Group Inc (REPL)

Baker Bros. Advisors Lp added to a holding in Replimune Group Inc by 3918.40%. The purchase prices were between $18.85 and $27, with an estimated average price of $22.78. The stock is now traded at around $48.50. The impact to a portfolio due to this purchase was 0.02%. The holding were 206,586 shares as of .

Added: Albireo Pharma Inc (ALBO)

Baker Bros. Advisors Lp added to a holding in Albireo Pharma Inc by 48.77%. The purchase prices were between $23.19 and $41.61, with an estimated average price of $29.06. The stock is now traded at around $35.77. The impact to a portfolio due to this purchase was 0.02%. The holding were 549,047 shares as of .

Added: Ovid Therapeutics Inc (OVID)

Baker Bros. Advisors Lp added to a holding in Ovid Therapeutics Inc by 28.92%. The purchase prices were between $5.39 and $8.24, with an estimated average price of $6.68. The stock is now traded at around $6.12. The impact to a portfolio due to this purchase was less than 0.01%. The holding were 590,761 shares as of .

Sold Out: Seagen Inc (SGEN)

Baker Bros. Advisors Lp sold out a holding in Seagen Inc. The sale prices were between $145.95 and $195.69, with an estimated average price of $167.15.

Sold Out: Principia Biopharma Inc (PRNB)

Baker Bros. Advisors Lp sold out a holding in Principia Biopharma Inc. The sale prices were between $56 and $101.07, with an estimated average price of $88.57.

Sold Out: Tricida Inc (TCDA)

Baker Bros. Advisors Lp sold out a holding in Tricida Inc. The sale prices were between $8.56 and $26.93, with an estimated average price of $14.73.

Sold Out: Aimmune Therapeutics Inc (AIMT)

Baker Bros. Advisors Lp sold out a holding in Aimmune Therapeutics Inc. The sale prices were between $11.99 and $34.45, with an estimated average price of $21.43.

Sold Out: Abeona Therapeutics Inc (ABEO)

Baker Bros. Advisors Lp sold out a holding in Abeona Therapeutics Inc. The sale prices were between $1.02 and $3.42, with an estimated average price of $2.52.

Sold Out: Matinas BioPharma Holdings Inc (MTNB)

Baker Bros. Advisors Lp sold out a holding in Matinas BioPharma Holdings Inc. The sale prices were between $0.67 and $0.96, with an estimated average price of $0.79.



Here is the complete portfolio of BAKER BROS. ADVISORS LP. Also check out:

1. BAKER BROS. ADVISORS LP's Undervalued Stocks
2. BAKER BROS. ADVISORS LP's Top Growth Companies, and
3. BAKER BROS. ADVISORS LP's High Yield stocks
4. Stocks that BAKER BROS. ADVISORS LP keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)